



32692

PATENT TRADEMARK OFFICE

Patent
Case No.: 52690US026

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor: GERSTER, JOHN F.

Application No.:

Group Art Unit: 1625

Filed:

Examiner: Morris, Patricia L.

Title:

PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on:

21 July 2003
Date

Renee A. Wolff
Signed by: Renee A. Wolff

Dear Sir:

Pursuant to 37 CFR §§ 1.56, 1.97, and 1.98, enclosed is a completed Form PTO-1449 citing references submitted for consideration by the Examiner. In accordance with 37 CFR § 1.98(d), copies of the references are not enclosed as they can be found in the file of the parent case, U.S. Application No. 10/180,678, filed June 26, 2002. It is respectfully requested that the Examiner initial and return the enclosed Form PTO-1449 to indicate that each reference has been considered.

It is believed that no fee is due; however, in the event a fee is required, please charge the fee to Deposit Account No. 13-3723.

Respectfully submitted,

21 July 2003
Date

By: Dean A. Ersfeld
Dean A. Ersfeld, Reg. No.: 46,689
Telephone No.: (651) 733-7830

Office of Intellectual Property Counsel
3M Innovative Properties Company
Facsimile No.: 651-736-3833

Substitut f r f rm 1449A/PTO (modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Page 1 of 3	Applicati n Number	
	Filing Dat	
	First Named Inventor	J hn F. Gerster
	Art Unit	1625
	Examiner Name	Morris, Patricia L.
	Attorney Case Number	52690US021

U.S. Patent Documents					
Exam. Init.*	Cite No.	Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Doc. Number-(Kind Code if Known)			
	A1	US- 3,314,941	04-18-1967	Littell et al.	
	A2	US- 4,689,338	08-25-1987	John F. Gerster	
	A3	US- 4,698,348	10-06-1987	John F. Gerster	
	A4	US- 4,929,624	05-29-1990	Gerster et al.	
	A5	US- 4,988,815	01-29-1991	Andre et al.	
	A6	US- 5,037,986	08-06-1991	John F. Gerster	
	A7	US- 5,175,296	12-29-1992	Gerster	
	A8	US- 5,238,944	08-24-1993	Wick et al.	
	A9	US- 5,266,575	11-30-1993	John F. Gerster	
	A10	US- 5,268,376	12-07-1993	John F. Gerster	
	A11	US- 5,346,905	09-13-1994	John F. Gerster	
	A12	US- 5,352,784	10-04-1994	Nikolaides et al.	
	A13	US- 5,367,076	11-22-1994	Gerster	
	A14	US- 5,389,640	02-14-1995	Gerster et al.	
	A15	US- 5,395,937	03-07-1995	Nikolaides et al.	
	A16	US- 5,446,153	08-29-1995	Lindstrom et al.	
	A17	US- 5,482,936	01-09-1996	Kyle J. Lindstrom	
	A18	US- 5,693,811	12-02-1997	Lindstrom	
	A19	US- 5,741,908	04-21-1998	Gerster et al.	
	A20	US- 5,756,747	05-26-1998	Gerster et al.	
	A21	US- 5,939,090	08-17-1999	Beaurline et al.	
	A22	US- 6,039,969	03-21-2000	Tomai et al.	
	A23	US- 6,069,149	05-30-2000	Nanba et al.	
	A24	US- 6,083,505	07-04-2000	Miller et al.	
	A25	US- 6,110,929	08-29-2000	Gerster et al.	
	A26	US- 6,194,425	02-27-2001	Gerster et al.	
	A27	US- 6,245,776	06-12-2002	Skwierczynski et al.	
	A28	US- 6,331,539	12-18-2001	Crooks et al.	

*Examiner:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute form 1449A/PTO (modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Page 2 of 3	Application Number	
	Filing Date	
	First Named Inventor	John F. Gerster
	Art Unit	1625
	Examiner Name	Morris, Patricia L.
	Attorney Case Number	52690US021

U.S. Patent Documents						
Exam. Init.*	Cite No.	Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Doc. Number-(Kind Code if Known)				
	A29	US- 6,376,669	04-23-2002	Rice et al.		
	A30	US- 2002/0055517 A1	05-09-02	Smith		
	A31	US- 2002/0058674 A1	05-16-02	Hedenstrom et al.		
	A32	US- 6,451,810	09-17-02	Coleman et al.		

Foreign Patent Documents							
Exam. Init.*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation (Check if yes)
		Ctry. Code	Number-KindCode (if known)				
	B1	PCT	WO 00/47719	08-17-2000			
	B2	PCT	WO 00/76518	12-21-2000			
	B3	PCT	WO 01/74343	10-11-2001			
	B4	PCT	WO 02/36592	05-10-2002			X
	B5	PCT	WO 02/46188	06-13-2002			
	B6	PCT	WO 02/46189	06-13-2002			
	B7	PCT	WO 02/46190	06-13-2002			
	B8	PCT	WO 02/46191	06-13-2002			
	B9	PCT	WO 02/46192	06-13-2002			
	B10	PCT	WO 02/46193	06-13-2002			
	B11	PCT	WO 02/46194	06-13-2002			
	B12	PCT	WO 02/46749	06-13-2002			
	B13	PCT	WO 02/102377	12-27-2002			
	B14	JP	9-208584	08-12-1997			
	B15	JP	9-255926	03-26-1999			X
	B16	JP	11-222432	08-17-1999			X
	B17	JP	2000-247884 (abs)	09-12-2000			X
	B18	EP	0 394 026	10-24-1990			
	B19	EP	1 104 764	06-06-2001			

*Examiner:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitut for form 1449A/PTO (modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Page 3 of 3	Applicati n Number	
	Filing Date	
	First Named Invent r	John F. Gerster
	Art Unit	1625
	Examiner Name	Morris, Patricia L.
	Attorney Case Number	52690US021

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS		
Exam. Init.*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C1	Wozniak, et al, "The Amination of 3-nitro-1, 5-naphthyridines by Liquid Ammonia/Potassium Permanganate ^{1,2} . A New and Convenient Amination Method.", <u>Journal of the Royal Netherlands Chemical Society</u> , 102, pp 511-513, December 12, 1983.
	C2	Brennan, et al, "Automated Bioassay of Interferons in Micro-test Plates", <u>Biotechniques</u> , June/July, 78, 1983.
	C3	Testerman, et al., "Cytokine Induction by the Immunomodulators Imiquimod and S-27609", <u>Journal of Leukocyte Biology</u> , Volume 58, pp. 365-372, September 1995.
	C4	Bachman, et al, "Synthesis of Substituted Quinolylamines. Derivatives of 4-Amino-7-Chloroquinoline", <u>J. Org. Chem.</u> , 15, pp 1278-1284 (1950).
	C5	Jain, et al, "Chemical and Pharmacological Investigations of Some ω -Substituted Alkylamino-3-aminopyridines", <u>J. Med. Chem.</u> , 11, pp 87-92 (1968).
	C6	Baranov, et al., <u>Chem. Abs.</u> 85, 94371, (1976).
	C7	Berényi, et al, "Ring Transformation of Condensed Dihydro-as-triazines", <u>J. Heterocyclic Chem.</u> , 18, pp 1537-1540 (1981).
	C8	Chollet, et al, "Development of a Topically Active Imiquimod Formulation", <u>Pharmaceutical Development and Technology</u> , 4(1), pp 35-43 (1999)

*Examiner:	Dat Consid red:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	